Orionis to receive $47 million upfront, as well as future milestone-related payments. Orionis will leverage its Allo-Glue™ platform for discovery of small molecule monovalent glues. September 20, 2023, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year…
News
Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer
Boston, MA & Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16…
Orionis Biosciences Demonstrates Platform Capabilities of Genome-scale Molecular Glue Discovery and Rational Design at Targeted Protein Degradation Summit
Boston, MA and Ghent, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today will present preclinical data supporting its Allo-GlueTM protein degradation platform for discovery and rational design of small molecule molecular glues at the 5th Annual Targeted Protein Degradation Summit, taking place…
Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic
October 19, 2022, BOSTON, MA and GHENT, Belgium – Orionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today announced it has completed a $55 million financing round and expanded its team, naming Robert Petit, Ph.D., as Senior Vice President, Early Clinical Development and Bihua Chen…
Orionis Presents at CNN’s Life Itself Conference
The first description of cancer in human history can be found in an ancient Egyptian medical text known as the Edwin Smith Papyrus. Yet almost 4,000 years later, cancer continues to plague humankind. What have we learned in the last millennia and where do we go from here? Orionis Chief Data Scientist Riccardo Sabatini presented…
